EGFR and non-small cell lung carcinoma: Currently, three generations of EGFR tyrosine kinase inhibitors (TKIs) are used in the treatment of non-small-cell lung cancer (NSCLC) patients with activating mutations in the EGFR gene, and ongoing clinical trials examine the safety and effectiveness of new third- and fourth-generations.